Funding Cycle XXVII – Letters of Intent Submission in November 2011

In 2012, the Roche Organ Transplantation Research Foundation (ROTRF) awarded 1'658'700 Swiss francs in the form of eight clinical research grants and a grant to support the BANFF Foundation. As in the previous five years, the projects funded by the ROTRF focus on important issues in transplantation and have potential for near-term clinical application.

In Cycle XXVII, Letters of Intent (LOI) for research projects were accepted up until the deadline of 1 November 2011. The ROTRF received 149 eligible LOIs. Most of the applications were received from North America (USA: 47%; Canada: 6.0%). European applications accounted for 41% of the LOI, with the major countries being the Netherlands (6.7%), UK, Italy (6% each), France, Germany (5.4% each), and Switzerland (3.3%). Of the remaining applications received, Australasia accounted for 4.0%, while less than 1% of applications were received from Asia, Africa and South America. Based on the Scientific Advisory Committee’s review, the Board of Trustees invited 29 applicants to submit a Full Paper Applications (FPA) and nine grants were awarded.

Applicants awarded grants in Cycle XXVII will investigate mechanisms predictive of spontaneous liver regeneration following acute failure, means of improving organ preservation to achieve better graft outcome, ways to assess organ quality at donation, mechanisms of tolerance and long-term graft survival, differences in allograft and viral responses, and non-invasive markers of allograft rejection. The Trustees also awarded a grant to the newly established Banff Foundation. This foundation represents the formalisation of the highly respected Banff Allograft Pathology Classification and Consensus Process. Its aims are to establish an internationally accepted diagnostic consensus and to combine pathological analyses of allografts with biology-based assessment of biopsy specimens. The Trustees believe that the formalisation of the Banff Consensus Process may be beneficial to the transplantation research community, ultimately benefitting transplant patients.